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Tyr1068-phosphorylated epidermal growth factor
receptor (EGFR) predicts cancer stem cell targeting by
erlotinib in preclinical models of wild-type EGFR
lung cancer
G Sette1,5, V Salvati1,5, M Mottolese1, P Visca1, E Gallo1, K Fecchi2, E Pilozzi3, E Duranti3, E Policicchio2,4, M Tartaglia2, M Milella1,
R De Maria1 and A Eramo*,2
Tyrosine kinase inhibitors (TKIs) have shown strong activity against non-small-cell lung cancer (NSCLC) patients harboring
activating epidermal growth factor receptor (EGFR) mutations. However, a fraction of EGFR wild-type (WT) patients may have an
improvement in terms of response rate and progression-free survival when treated with erlotinib, suggesting that factors other
than EGFR mutation may lead to TKI sensitivity. However, at present, no sufficiently robust clinical or biological parameters have
been defined to identify WT-EGFR patients with greater chances of response. Therapeutics validation has necessarily to focus on
lung cancer stem cells (LCSCs) as they are more difficult to eradicate and represent the tumor-maintaining cell population. Here,
we investigated erlotinib response of lung CSCs with WT-EGFR and identified EGFR phosphorylation at tyrosine1068 (EGFRtyr1068)
as a powerful biomarker associated with erlotinib sensitivity both in vitro and in preclinical CSC-generated xenografts. In contrast
to the preferential cytotoxicity of chemotherapy against the more differentiated cells, in EGFRtyr1068 cells, erlotinib was even more
active against the LCSCs compared with their differentiated counterpart, acquiring potential value as CSC-directed therapeutics in
the context of WT-EGFR lung cancer. Although tumor growth was inhibited to a similar extent during erlotinib or chemotherapy
administration to responsive tumors, erlotinib proved superior to chemotherapy in terms of higher tolerability and reduced tumor
aggressiveness after treatment suspension, substantiating the possibility of preferential LCSC targeting, both in adenocarcinoma
(ADC) and squamous cell carcinoma (SCC) tumors. We conclude that EGFRtyr1068 may represent a potential candidate biomarker
predicting erlotinib response at CSC-level in EGFR-WT lung cancer patients. Finally, besides its invariable association with
erlotinib sensitivity in EGFR-WT lung CSCs, EGFRtyr1068 was associated with EGFR-sensitizing mutations in cell lines and patient
tumors, with relevant diagnostic, clinical and therapeutic implications.
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Non-small-cell lung cancer (NSCLC) accounts for ∼ 80% of
lung cancer subtypes and is the leading cause of cancer-
related death worldwide.1 In recent years, molecular char-
acterization of NSCLC has reached an unprecedented detail
and has allowed segregating NSCLC into discrete molecular
subgroups, characterized by specific oncogenic drivers, such
as epidermal growth factor receptor (EGFR), BRAF, KRAS,
epidermal growth factor receptor 2 (HER2) mutations, MET
amplification and anaplastic lymphoma kinase gene rearran-
gements (ALK).2,3 Consequently, the understanding of
NSCLC biology has brought two new classes of targeted
agents into the clinical setting: EGFR tyrosine kinase inhibitors
(TKIs) and ALK inhibitors.4,5 In particular, clinical trials have
shown that NSCLC patients whose tumors harbor sensitizing
EGFR mutations significantly benefit from the upfront use of
an EGFR TKI, rather than conventional chemotherapy.6–11
Although licensed for clinical use in chemotherapy-pretreated
patients, regardless of EGFRmutational status, the EGFRTKI
erlotinib has limited efficacy when compared with standard
chemotherapy in patients with WT-EGFR NSCLC.12–14
However, a fraction of patients on erlotinib treatment may
achieve clinically significant objective responses and pro-
longed disease control, despite the lack of detectable EGFR
mutations.15 Nevertheless, no biomarker investigated so far
was felt sufficiently robust to select for the use of erlotinib in the
maintenance or refractory setting.16 Thus, it would be crucial
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to identify molecular predictors of TKI sensitivity in EGFRwild-
type (WT) tumors in order to prospectively select the subgroup
of patients who may benefit from erlotinib therapy. Moreover,
EGFR TKIs have also shown a modest therapeutic effect in
lung squamous cell carcinoma (SCC), where EGFRmutations
are very rare and patients have limited therapeutic options in
the maintenance and relapsed settings.16–20
Even more importantly, in order to obtain meaningful clinical
responses it is crucial to effectively target the population of
cells that are able to escape treatment andmaintain the growth
of a resistant tumor.21 Cancer stem cells (CSCs) have been in
fact identified within most solid tumors, including lung tumors,
and are associated with increased resistance to
therapies.22–30 Thus, the efficacy of innovative therapeutic
strategies should be validated against these more aggressive,
tumor-maintaining cells.23,27,31 Importantly, TKI response has
never been determined at the level of the tumor-maintaining
CSCs. Thus, we investigated erlotinib response of EGFR
mutation-negative lung cancer stem cells (LCSCs) and LCSC-
based xenografts with the attempt to evaluate their sensitivity
to the drug and correlate it with their molecular pattern in order
to identify potential biomarkers predictive of erlotinib response
in a WT-EGFR context at the CSC level.
Results
Validation of LCSCs and response to EGFR TKI. LCSCs
from WT-EGFR NSCLC patients with SCC (n=3), adeno-
carcinoma (ADC, n= 3) and large-cell neuroendocrine
carcinoma (LCNEC, n= 1; Table 1a) were isolated as tumor
spheres in serum-free culture conditions that enrich cultures
for undifferentiated tumor cells endowed with stem cell
properties of long-term proliferation capacity, increased
clonogenic potential, differentiation ability, chemoresistance,
increased tumorigenicity and ability to generate xenografts
that mimic the tumor of origin, as we previously
reported24,32,33 and have shown in Figure 1. Functional
response of LCSC to erlotinib over 2-day in vitro exposure
was then assessed in comparison with standard chemother-
apy: cisplatin, gemcitabine, pemetrexed for ADC-derived
LCSC, cisplatin, gemcitabine, docetaxel for SCC-derived
LCSC and cisplatin, etoposide, gemcitabine or docetaxel for
LCNEC-derived LCSCs. Four out of seven LCSC cell lines
(SCC: LCSC3 and LCSC4; ADC: LCSC5 and LCSC6) were
strikingly sensitive to erlotinib, with 450% reduction in cell
viability; in these cells, erlotinib was as effective or more
effective than cisplatin-based chemotherapy doublets
(Figure 2a). Massive cell death was observed in erlotinib-
Table 1A Clinical staging and classification of lung cancer samples and mutational status of the lung cancer-associated gene in the corresponding LCSCs
Tumor type KRAS EGFR EML4-ALK fusion PTEN PI3KCA HER2
LCSC1 LCC-NE (pT2pN2pMx-IIIA WT WT No WT WT WT
LCSC2 SCC (pT2pN2pMX(IIIA)-G2) WT WT No WT WT WT
LCSC3 SCC (pT3pN0pMx-IIB-G3) WT WT No WT WT WT
LCSC4 SCC (pT2N0-IB) Mut G12C(ggt4tgt) WT No WT WT WT
LCSC5 AC (pT2pN2pMx-IIIA-G2) WT WT No WT WT WT
LCSC6 AC (pT4pN1IIIA-G3) Mut G12C(ggt4tgt) WT No WT WT WT
LCSC7 AC (pT2a pN0 M1-G3) WT WT No WT WT WT
Table 1B Descriptive tables of EGFR (upper table) and HER2 (lower table) FISH analysis in LCSCs
CSC cell line EGFR gene copy
number (mean)
CHR 7 centromere
copy number (mean)
Ratio
EGFR/Chr7
EGFR
gene status
No. of
counted cells
LCSC1 5.9 2.01 2.92 Amplificationa 185
LCSC2 5.2 2.9 1.79 Gainb 138
LCSC3 10.3 3.71 2.77 Amplificationa 253
LCSC4 8.5 2.65 3.2 Amplificationa 180
LCSC5 9.2 3.26 2.82 Amplificationa 178
LCSC6 2.24 1.68 1.34 NAc 123
LCSC7 2.26 1.98 1.14 NAc 100
CSC cell line HER2 gene copy
number (mean)
CHR 17 centromere
copy number (mean)
Ratio
HER2/Chr17
HER2
gene status
No. of
counted cells
LCSC1 3 2 1.5 NAc 100
LCSC2 4 2 42 Amplificationa 120
LCSC3 410 2 42 Amplificationa 115
LCSC4 3 2 1.5 NAc 80
LCSC5 2 2 1 NAc 100
LCSC6 3 2 1.5 NAc 60
LCSC7 2 3 0.6 NAc 100
aAmplification: ratio (EGFR/Chr7 and HER2/Chr17)42
bIncreased gene copy number and chr7 polysomy
cNo amplification, no polysomy
Erlotinib response of lung CSC with wild-type EGFR
G Sette et al
2
Cell Death and Disease
sensitive LCSCs after longer (3 days) drug exposure
(Figure 2b). Among other clinically relevant TKI inhibitors,
cetuximab was essentially devoid of significant antitumor
activity against LCSCs, whereas gefitinib displayed a sub-
stantial cytotoxic activity against the same erlotinib-sensitive
LCSCs (Supplementary Figure 1A). Thus, sensitivity of
LCSCs toward EGFR inhibition is not limited to erlotinib, but
may be a general response to small=molecule EGFR
inhibitors.
Molecular characterization of LCSCs. EGFR, HER2,
KRAS, PTEN and PI3K were sequenced for cancer-
associated mutations (Table 1a, Supplementary Table 1 and
Supplementary Information); in addition, HER2 and EGFR
copy numbers or EML4-ALK (echinoderm microtubule-
associated protein-like 4–anaplastic lymphoma kinase) rear-
rangement were evaluated by FISH (Table 1b and
Supplementary Information). The entire EGFR gene sequen-
cing was performed to evaluate the possible occurrence of
EGFR mutations outside the clinically relevant regions (exons
18 through 21). No mutations in the EGFR, PTEN and
PIK3CA genes or EML4-ALK fusions were found in the panel
of LCSC lines analyzed (Table 1a); LCSCs 4 and 6 (SCC and
ADC, respectively) displayed KRAS G12C (Table 1a,
Supplementary Table 2 and Supplementary Information).
However, EGFR gene copy number was increased in 5 out of
7 LCSCs and frankly amplified in 4 (Table 1b); the HER2
gene was frankly amplified in two SCC-derived LCSC cell
lines (Table 1b).
EGFRtyr1068 is associated with erlotinib sensitivity in
EGFR-WT LCSCs. Partial correlation among erlotinib
response of LCSCs and EGFR amplification was found. As
expected, most LCSC lines with amplified EGFR were
sensitive to erlotinib; however, LCSC1 displayed amplified
EGFR and Erlotinib resistance, whereas LCSC6 displayed
nonamplified EGFR and erlotinib sensitivity (Table 1b and
Figure 2b). In the absence of EGFR mutations, we next
evaluated EGFR protein expression and phosphorylation
status in LCSCs. Strikingly, erlotinib-sensitive LCSCs dis-
played variable EGFR protein overexpression and highly
consistent phosphorylation of the tyrosine 1068 (EGFRtyr1068)
residue, as opposed to resistant LCSCs (Figure 2c). Con-
versely, tyrosine 1173 phosphorylation (EGFRtyr1173) was
barely detectable (Figure 2c), as was phosphorylation of
other EGFR sites including tyr1045 or tyr845 (not shown).
We found broadly activated Akt, Erk or Stat3 pathways
downstream of EGFR in both erlotinib-sensitive and -resistant
LCSCs, without a discernible pattern (Figure 2c). Most
LCSCs displaying high levels of EGFR expression and
activation (LCSCs 3, 4, 5) harbored increased copies of
EGFR gene (48), suggesting that increased EGFR gene
Figure 1 (a) LCSCs generated subcutaneous patient-like xenografts in NOG mice. Hematoxylin–eosin-stained sections of patient tumors (left panels) and mouse xenografts
(right panels) obtained with the indicated LCSCs. Magnification is × 20 and scale bar corresponds to 50 μm. LCC-NE, large-cell neuroendocrine carcinoma; SCC, squamous cell
carcinoma; ADC, adenocarcinoma. (b) The in vitro differentiated LCSCs show decreased CSC-related gene expression. Immunoblot for SOX2 or ALDH1 in the indicated LCSCs
(-S) or their in vitro differentiated progeny (-D). (c) The in vitro differentiated LCSCs gain chemosensitivity. Control or chemo-treated LCSCs and their corresponding in vitro
differentiated progeny were left untreated (control) or exposed to cisplatin (CIS), gemcitabine (GEM) or docetaxel (DTX). Cell viability was measured after 48 h. Mean±S.D. of
three independent experiments is shown. *Po0.05; **Po0.01; ***Po0.001
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copies may contribute to overexpression and consequent
activation of the receptor (Table 1). However, in LCSC6,
EGFR was highly expressed and phosphorylated in the
absence of increased gene copies, suggesting that other
mechanisms may contribute to the activation of EGFR in this
context (Figure 2c and Table 1b). Moreover, LCSC1 displayed
EGFR amplification in the absence of EGFR activation or
sensitivity. These results indicate that EGFR amplification
does not always correlate with EGFR activation or erlotinib
response in LCSCs. Overall, these data suggest that
EGFRtyr1068 may represent a putative additional biomarker
for EGFR TKI sensitivity in LCSCs.
Erlotinib preferentially kills WT EGFRtyr1068 LCSCs
compared with their differentiated progeny. We evaluated
the long-term effect of erlotinib on LCSCs in colony formation
assay. Erlotinib treatment dramatically reduced the ability of
LCSCs with activated EGFR to generate colonies in soft agar
assay, demonstrating long-term efficacy of the drug and its
ability to target the clonogenic cells (Figure 2d). We next
Figure 2 Cytotoxic activity of chemotherapy or erlotinib and EGFR pathway activation in LCSCs. (a) LCSCs were exposed to the indicated drugs and cell viability evaluated
after 48 h and indicated as percentage versus control cells. (b) Time course of erlotinib-induced cytotoxicity. Cell viability was evaluated by CellTiter-Glo after 48 and 72 h of
erlotinib exposure. (c) Immunoblot analysis of the indicated components of the EGFR pathways. (d) Long-term effects of erlotinib on LCSCs. Percentage of clonogenic cells in soft
agar assay of erlotinib-treated versus control is indicated for each LCSC analyzed. (e) Cytotoxic activity of erlotinib in LCSCs (-S) and corresponding differentiated cells (-D) of
each sample as indicated. Cells were exposed to erlotinib for 3 days and cell viability evaluated by CellTiter-Glo. (f) Immunoblot comparison of EGFR expression and activation in
LCSCs (-S) and their in vitro differentiated counterparts (-D). Mean±S.D. of three independent experiments is always shown. *Po0.05; **Po0.01; ***Po0.001
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compared LCSC response with erlotinib and EGFR activation
level with that of their in vitro differentiated counterpart
(Figures 2e and f). In erlotinib-sensitive LCSCs, EGFRtyr1068
expression was more prominent in stem versus in vitro
differentiated cell populations (Figure 2f). Consistent with the
proposed role of EGFRtyr1068 in marking an EGFR-addicted
functional state, erlotinib-induced cytotoxicity against LCSCs
was even more marked than that observed in the differ-
entiated cells (Figure 2e). In vitro differentiation was
substantiated by reduction of embryonic gene expression
(ALDH1, SOX2) and gain of chemosensitivity, as shown in
Figures 1b and c and our previous data.32,33 In line with these
results, drug treatment of the LCSC population determined a
reduction of the stemness-related aldehyde dehydrogenase
(ALDH) expression. Based on the assumption that tumor
spheres are highly enriched in CSCs although containing
cells with lower degree of stemness, these results confirm
that erlotinib preferentially killed the more undifferentiated
cells within the LCSC culture (Supplementary Figure 1B).
EGFRtyr1068 association with EGFR-sensitizing mutations
in lung cancer cell lines and patient tumors. Based on the
results reported above, we extended the study to a panel of
commercial lung cancer cell lines. All of the cell lines with
known EGFR-activating mutations (HCC827, H1975 and
H1650) and the EGFR-WT Calu3 cell line displayed
prominent EGFRtyr1068 phosphorylation and were sensitive
(o30% reduction of cell viability) to erlotinib (Supplementary
Figures 2A–C). Conversely, EGFRtyr1173 was not associated
with EGFR mutational status or erlotinib sensitivity
(Supplementary Figures 2A–C).
We also analyzed the expression of EGFRtyr1068 and
EGFRtyr1173 in a series of 91 lung cancer specimens, with
(n=39) orwithout (n=52)EGFR-sensitizingmutations (Table 2).
In this series, EGFRtyr1068was preferentially expressed inEGFR-
mutant samples (score 2+/3+ in 64%of EGFR-mut cases versus
38% of EGFR-WT cases, respectively; P=0.03), whereas
EGFRtyr1173 similarly distributed in EGFR-mut and EGFR-WT
samples (score 2+/3+ in 38% and 37% of cases, respectively;
P=0.97) (Table 2c). Overall, these data support the idea that
EGFRtyr1068, as opposed to EGFRtyr1173, marks an EGFR
activation state driven by activating EGFR genemutations; when
constitutively present in an EGFR-WT genetic context, such
activation state may still portend sensitivity to EGFR TKI even in
the absence of EGFR gene mutations.
Erlotinib treatment-induced EGFR pathway downregula-
tion and apoptosis in LCSCs with activated EGFR. At the
molecular level, erlotinib induced EGFR pathway down-
regulation in all LCSCs bearing activated receptor.
EGFRtyr1068 and all downstream mediators of EGFR signal-
ing analyzed, p-STAT3, p-AKT and p-ERK, although
expressed at variable extent in the different samples,
displayed consistent decrease in sensitive LCSCs after
erlotinib exposure (Figure 3a). These results suggest that
decreased activation of all pathways contributed to mediate
erlotinib-induced toxicity in LCSCs, and this is in agreement
with previously reported data in lung cancer cell lines.34,35
Analysis of DNA content by propidium iodide staining and
flow cytometry analysis of control and erlotinib-treated cells
revealed the appearance of the sub-diploid DNA peak,
hallmark of apoptosis, specifically in erlotinib-sensitive
treated samples. A 20% (LCSC3) or 32.5% (LCSC5)
increase in the apoptotic cells fraction was measured in
sensitive LCSCs, whereas a negligible variation was detected
in resistant LCSC2 and LCSC7 after erlotinib exposure
(Figure 3b). Decrease of the anti-apoptotic protein Bcl-xL
(B-cell lymphoma-extra large) and cleavage of caspase-3
detected by immunoblotting further confirmed that erlotinib
cytotoxicity occurred through apoptosis induction in respon-
sive cells (Figure 3c).
Table 2A Correlation between EGFR, pEGFRtyr1068 and pEGFRtyr1173 expres-
sion and EGFR mutational status in 91 NSCLC patient tumors. (a) Patient
information and clinical–pathological characteristics of NSCLC tumors
Patient and tumor information No. of patients Percentage (%)
Gender/age
Male 40 44%
Female 51 56%
Median age 60.6
Histotype
Adenocarcinoma 76 83%
Squamous carcinoma 9 10%
Other 6 7%
Grading
G1 1 1%
G2 25 28%
G3 44 48%
Unknown 21 23%
Stage
I 9 10%
II 4 4%
III 16 18%
IV 38 42%
Unknown 24 26%
EGFR status
WT 52 57%
MUT 39 43%
Table 2B Correlation between EGFR, pEGFRtyr1068 and pEGFRtyr1173 expres-
sion and EGFRmutational status in 91 NSCLC patient tumors. (b) Type of EGFR
gene mutation in the 39 mutated NSCLC tumors
EGFR mutation
Exon 18 Exon 19 Exon 21
1(G719X) 2.5% 20 (deletions) 51% 13 (L858R) 34%
1 (P741S) 2.5% 1 (P848L) 2.5%
1 (V742I) 2.5% 1 (A859T) 2.5%
1 (G873E) 2.5%
TOT 2.5% TOT 56% TOT 41.5%
Table 2C Relationship between negative and positive p-EGFR1068/1173 in
EGFR mutated (mut) or nonmutated (WT) patient samples
p-EGFRTyr1068 p-EGFRTyr1173
0/1+ 2+/3+ 0/1+ 2+/3+
Mut 36% 64% 62% 38%
WT 62% 38% 63% 37%
Percentages of negative/weakly positive (0/1+) or positive (2+/3+) staining are
indicated
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Figure 3 Erlotinib-induced EGFR pathway downmodulation and cell death in sensitive LCSCs. (a) Immunoblot analysis of the indicated EGFR pathway components in
control or 2-day erlotinib-treated sensitive (LCSC3 and LCSC5) or resistant (LCSC2 and LCSC7) LCSCs. Flow cytometric quantification of propidium iodide-stained apoptotic
cells (b) and immunoblot analysis of Bcl-xL and caspase-3 cleavage (c) in the same cells as in (a) exposed to erlotinib for 3 days. (b) Percentage of subdiploid/apoptotic cells is
indicated± S.D.
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Specificity of erlotinib antitumor activity in
LCSC-generated ADC xenografts with activated EGFR.
In order to evaluate the antitumor activity of erlotinib in vivo,
LCSCs of ADC subtype either bearing or lacking EGFRtyr1068
were used to generate subcutaneous tumors and erlotinib
was administered by oral gavage, following clinically used
dosages and regimens, to ensure systemic drug concentra-
tions comparable to those reached in clinical context.
EGFRtyr1068 could be detected in CSC-generated xenografts,
its expression correlated with that found in the corresponding
LCSCs they were generated from and decreased following
Erlotinib treatment in vivo, indicating that the erlotinib
concentration achieved within the tumor was sufficient to
inhibit EGFR activity (Figure 4a). The levels of EGFRtyr1068
were reduced in xenografts compared with the LCSCs,
confirming the reduced EGFR activation also observed
following differentiation in vivo (Figures 2e and 4a). Thus, we
assumed that LCSC-generated xenografts constituted a highly
reliable preclinical system suitable to be used to investigate
erlotinib activity in vivo. Tumor growth was significantly inhibited
by erlotinib exclusively in xenografts derived from EGFR-
activated LCSCs, supporting the results in vitro (Figure 4b).
Thus, erlotinib exerted a marked antitumor activity in vivo
exclusively in EGFRtyr1068-positive CSC-generated xenografts.
Erlotinib antitumor activity in xenografts generated by
ADC and SCC LCSCs with activated EGFR is superior
than chemotherapy. Chemotherapy is currently the stan-
dard of care for ADC lung cancer patients in the absence of
EGFR or other targetable molecular alterations (EML4-ALK),
with erlotinib approved only for EGFR-mutated ADC patients
in first-line treatment. As we found that the lung ADC CSC-
derived xenografts with activated WT-EGFR are highly
sensitive to erlotinib in vivo, we compared erlotinib with
chemotherapy antitumor activity in this preclinical in vivo
model in view of a possible therapeutic use of erlotinib for
subgroups of mutation-negative patients with activated
receptor.
Moreover, not only ADC but also SCC type of LCSCs were
highly sensitive to erlotinib in vitro (Figure 2a). Therefore, we
investigated the in vivo activity of erlotinib in comparison with
that of chemotherapeutic doublets (cisplatin/pemetrexed for
ADC and cisplatin/gemcitabine for SCC). During drug treat-
ment, growth was impaired to a similar extent by erlotinib
and chemotherapy in both xenograft models derived from
EGFRtyr1068-positive LCSCs (Figure 5a). Erlotinib was highly
tolerated at the used dosages as it did not determine adverse
effects in treated mice, except for a light body weight loss.
In contrast, chemotherapy was highly toxic determining
marked weight loss in all mice and toxic deaths in a few mice
(Figure 5a, bottom panels). Tumor growth inhibition was
clearly visible in excised xenografts and was associated with
decrease of EGFRtyr1068 in treated tumors (Figure 5b).
Following treatment interruption, chemotherapy pretreated
tumors started to overgrow to a rate much higher than control
xenografts, as expected for tumors whose more aggressive
tumorigenic cells are spared by chemotherapy and in line with
the clinical behavior of chemo-relapsed patient tumors
(Figure 5c). In line with their increased growth rate, tumor
cells obtained from chemo-treated tumors displayed an
augmented expression of the CSC-related genes ALDH1
and NOTCH3 compatible with a higher CSC content and
supporting the evidence of a more aggressive phenotype of
tumors following chemotherapy (Figure 5d). Although highly
expressed in the ADC LCSCs, the CSC-related gene SOX2
was undetectable in corresponding xenograft, suggesting that
its expression was drastically abolished following differentia-
tion in vivo, confirming the results observed in vitro (Figures 1b
and 5d). Thus, as the expression of SOX2 was likely restricted
to the small CSC subpopulation, the limited protein amount in
xenografts did not allow its detection.
Figure 4 EGFR activation and Erlotinib antitumor activity in LCSC-derived ADC xenografts. (a) Immunoblot analysis of EGFRtyr1068 in sensitive (LCSC5) or resistant (LCSC7)
LCSCs and in the corresponding xenografts untreated (− ) or treated (+) with erlotinib. (b) Growth curves of the same control or erlotinib-treated xenografts as in (a). Mean± S.D.
of three independent experiments is shown. ***Po0.001
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In contrast, reduced expression of CSC-related genes was
observed in tumors following erlotinib therapy, consistent with
a lower CSC content of erlotinib-treated tumors, in line with
their decreased growth rate and supporting the assumption of
a preferential activity of erlotinib against the tumor-maintaining
cells also in vivo (Figure 4d). Finally, in agreement with in vitro
results, we found that erlotinib antitumor activity also occurred
through apoptosis induction in vivo, as demonstrated by the
reduction of pro-caspase 3 and the antiapoptotic protein
Bcl-XL in cell lysates derived from erlotinib-treated xenografts
in comparison with controls (Supplementary Figure 3).
Discussion
EGFR-activating mutations have been widely proven to be
associated with increased patient response to anti-EGFR
therapies, thus becoming the indication for erlotinib treatment
in NSCLC patients of ADC subtype.7 Although secondary
Figure 5 The in vivo antitumor activity of Erlotinib or chemotherapy in LCSC-generated adenocarcinoma (ADC) or squamous cell carcinoma (SCC) xenografts. (a, upper
panels) Growth curves of LCSC-derived xenografts in control mice or mice treated with erlotinib, cisplatin/pemetrexed combination (Cis+Pem) or cisplatin/gemcitabine
combination (Cis+Gem), as indicated (). Mean± S.D. of three independent experiments is shown. *Po0.05; **Po0.01. (a, lower panels) Table of drug-induced systemic toxicity
in the three groups of mice indicated as percentage of body weight loss (BWL) or number of deaths/total number of mice. (b) Images of tumors at the end of each treatment and
immunoblot analysis of EGFR/pEGFRtyr1068 in cells obtained from control or treated tumors. (c) Relative tumor growth of control or pretreated tumors after treatment interruption.
Relative tumor growth is indicated as ratio of tumor volume at the indicated week after drug suspension versus volume at the last day of treatment. *Po0.05; **Po0.01;
***Po0.001. (d) Immunoblot analysis of the indicated CSC-related proteins in control or treated xenografts in comparison with their corresponding LCSCs
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resistance invariably occurs because of multiple mechanisms,
erlotinib therapy has proved superior to chemotherapy in the
subgroup of EGFR-mut patients, in term of increased
response rate and reduced toxicity.7–11,36 However, EGFR
mutations occur with low frequency (∼30%) in ADC subtype
and are virtually absent in SCC in the Caucasian population,
and thus most patients are currently excluded from erlotinib
therapeutic option either as first-line therapy or in recurrence/
maintenance clinical protocols, following chemotherapeutic
regimen failure.37 Consequently, treatment of EGFRmutation-
negative patients represents a relevant issue in NSCLC
management, considering the scarcity of therapeutic oppor-
tunities available, particularly for SCC patients. Importantly, a
fraction of NSCLC patients have displayed partial response to
erlotinib despite lack of EGFR mutations and the identification
of molecular biomarkers of response would be of great clinical
value to prospectively select those EGFR-WT patients who
are likely to benefit from erlotinib therapy.16–19
As it has been widely accepted that most solid tumors,
including lung tumors, arise and are maintained by CSCs, and
that chemotherapy-spared CSCs are responsible for tumor
recurrence, it is clear that biomarkers predicting erlotinib
response in EGFR-WT tumors have to be determined at the
CSC level. In this study, we investigated erlotinib response of
LCSCs with WT-EGFR and identified EGFR phosphorylation
at tyrosine 1068 (EGFRtyr1068) as a powerful biomarker
associated with strong erlotinib sensitivity both in vitro and in
preclinical CSC-generated subcutaneous xenografts. Impor-
tantly, in contrast to the preferential activity of chemotherapy
against differentiated cells, erlotinib cytotoxicity was even
more marked against the LCSCs than against their differ-
entiated counterpart both in vitro and in xenografts, acquiring a
great value as a CSC-directed therapeutic drug in the context
of WT-EGFR lung cancers. Although displaying similar ability
to inhibit tumor growth during treatment, erlotinib proved
superior to chemotherapy in terms of tolerability and reduced
tumor aggressiveness following treatment interruption. Among
the two most relevant sites of phosphorylation, tyr1068 and
tyr1173, only tyr1068 was phosphorylated in LCSCs, thus
increasing the relevance of this site of phosphorylation as a
biomarker associated with the tumor-maintaining cells, and
thus representing a potential therapeutic target for a long-
lasting therapeutic inhibition.
Finally, besides its invariable association with erlotinib
sensitivity in EGFR-WT LCSCs, EGFRtyr1068 was associated
with EGFR-sensitizing mutations in cell lines and patient
tumors, with relevant diagnostic and therapeutic implication.
Correlation of EGFRtyr1068 expression and EGFR inhibitor
sensitivity was also found in commercial lung cancer cell lines,
where EGFRtyr1068 was strictly associated with sensitivity
regardless of EGFR mutational status. In contrast,
EGFRtyr1173 was not correlated with sensitivity or mutation
(Supplementary Figure 2). Among the erlotinib-responsive
lung cancer cell lines, we found that H1975 and H1650 cells
were endowed with a lower degree of sensitivity to the drug
compared with HCC827, in agreement with the previously
demonstrated modulation of erlotinib response by lack of
functional PTEN (H1650) or by the concomitant presence of
the T790M EGFR resistance mutation (H1975) in these
cells.38–40 This result suggested that an intact AKT inhibitory
signaling (PTEN) is required for erlotinib-induced cytotoxicity
of lung cancer cells with mutated EGFR. Similarly, it is likely
that the genetic background of EGFR-activated lung cancer
cells may also modulate the extent of erlotinib sensitivity in
EGFR-WT cells. We found that LCSC4 and LCSC6 were
highly sensitive to erlotinib despite the presence of mutated
KRAS (Kirsten rat sarcoma), indicating that KRAS mutation
does not affect erlotinib-induced cytotoxicity in LCSCs with
WT/activated receptor (Table 1a and Figure 2). This result is in
agreement with previous reports showing that although KRAS
mutation is a general negative prognostic factor, lung cancer
patient response to erlotinib is independent of KRAS
status.41,42 Erlotinib dose used in vitro belongs to the higher
ranges of drug concentrations used in other studies with
EGFR-mutated cell lines that may display higher responsive-
ness to EGFR inhibition, particularly at lower doses. Never-
theless, at the used concentration, erlotinib displayed strong
activity against the LCSCswith EGFRtyr1068 in vitro. Moreover,
doses and schedules used in vivo were compatible with those
used in clinical setting, and under these conditions treatment
was endowed with high antitumor activity specifically against
the WT/activated EGFR tumors and highly tolerated, exclud-
ing the possibility that the observed in vitro activity of erlotinib
could result from drug overdosage, not achievable in vivo.
We found that erlotinib sensitivity of EGFR-WT LCSCs was
even higher when compared with their differentiated counter-
part, in line with their higher level of receptor activation (Figure
2e and f). It has been reported that in EGFR-mutated lung
cancer cell lines EGFR blockade may enrich for lung cancer
stem-like cells that resist the treatment.43 The apparent
discrepancy may lay in the type of EGFR activation occurring
in EGFR-mutated or -WT cells. In EGFR-WT context we
showed that the activation of EGFR ismodulated in the different
cell compartments, with the extent of EGFR activation markedly
higher in the CSCs compared with differentiated cells,
substantiating the latter reduced sensitivity to erlotinib. In
contrast, gene mutation-dependent EGFR activation, being
constitutive, might not vary in different cell compartments
determining a similar basal potential of response in CSCs and
differentiated cells. In spite of this, EGFR activation being equal,
the response to erlotinib may be reduced in the CSCs because
of their intrinsic pro-survival CSC properties (drug extrusion
ability, expression of resistance genes, increased ability to
escape cell death, etc.). Based on these assumptions, it is
reasonable that erlotinib treatment could spare LCSCs in the
mutated-EGFR context, whereas it may preferentially target
LCSCs in EGFR mutation-negative tumors.
Erlotinib also displayed a stricking antitumor efficacy in
EGFRtyr1068-positive LCSC-generated xenografts. Erlotinib
and chemotherapy inhibited tumor growth rate to a similar
extent during drug administration, although chemotherapy
determined a massive systemic toxicity in a fraction of
animals, whereas erlotinib was highly tolerable (Figure 4a).
However, after treatment interruption, chemotherapy-exposed
tumors displayed increased aggressiveness, as expected for
tumors whose more malignant tumorigenic cells are spared by
chemotherapy and in line with the behavior of chemo-treated
clinical tumors. In contrast, growth rate of erlotinib-pretreated
tumors was even inferior than control tumors, and expression
of CSC-related genes was decreased, consistent with a minor
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CSC content of these tumors and supporting the in vitro
evidence of a preferential CSC-directed cytotoxicity by
erlotinib. Thus, we found that the antitumor efficacy exerted
by erlotinib in xenografts generated by EGFRtyr1068-positive
LCSCs was superior to that obtained with chemotherapy in
terms of long-term efficacy and tolerability and, importantly, it
occurred both in ADC and SCC lung cancer subtypes, with
relevant clinical implication as SCC patients have very limited
therapeutic options besides chemotherapy, at present.
Moreover, we found that EGFRtyr1068, and not EGFRtyr1173,
was associated with EGFR-sensitizing mutations in cell lines
and patient tumors. Thus, EGFRTyr1068 was associated with
lung cancer cells and tumors bearing EGFR-sensitizing
mutations or with lung cancer cells and LCSCs that were
sensitive to erlotinib treatment despite lack of EGFR mutation.
In this hypothesis, EGFRtyr1068 immunohistochemistry could
represent a surrogate tool besides EGFR sequencing analysis
to predict potential erlotinib sensitivity, applicable also among
mutation-negative patients and CSC based. However, future
studies of patient outcomewill contribute to determinewhether
the level of EGFRtyr1068 detected in patient tumors would
identify mutation-negative tumors with activated receptor,
more likely responsive to erlotinib.
In conclusion, our studies add a potential further level of
molecular determinants for erlotinib sensitivity besides gene
mutation, amplification or increased copy number that have
been considered for clinical studies so far but do not always
take for granted EGFR activation or erlotinib response.
Materials and Methods
Isolation and culture of lung cancer stem cells. Tumor samples were
obtained in accordance with consent procedures approved by the internal review
board of Department of Laboratory Medicine and Pathology, Sant’Andrea Hospital,
University La Sapienza, Rome. Tumor tissue dissociation and procedures for medium
preparation and expansion of LCSC in vitro were performed as we previously
described.24 Briefly, tissue dissociation of surgical specimens was carried out by
enzymatic digestion (20 μg/ml collagenase II, 20 μg/ml DNAse I, Gibco-Invitrogen,
Carlsbad, CA, USA) for 2 h at 37 °C. Recovered cells were cultured in serum-free
medium containing 50 μg/ml insulin, 100 μg/ml apo-transferrin, 10 μg/ml putrescine,
0.03 μM sodium selenite, 2 μM progesterone, 0.6% glucose, 5 mM hepes, 0.1%
sodium bicarbonate, 0.4% BSA, glutamine and antibiotics, dissolved in DMEM-F12
medium (Gibco-Invitrogen) and supplemented with 20 ng/ml EGF and 10 ng/ml b-FGF.
Flasks nontreated for tissue culture were used in order to reduce cell adherence and
support growth as undifferentiated tumor-spheres. Medium was replaced or
supplemented with fresh growth factors twice a week until cells started to grow,
forming floating aggregates. Cultures were expanded by mechanical dissociation of
spheres, followed by replating of both single cells and residual small aggregates in
complete fresh medium. In order to obtain differentiation of lung cancer sphere-
forming cells, stem cell medium was replaced with bronchial epithelial cell growth
medium (BEGM, Lonza, East Rutherford, NJ, USA) in tissue culture-treated flasks to
allow cell attachment and differentiation. Loss of stem cell markers and functions as
well as gain of chemosensitivity were considered for LCSC validation (Figure 1a and
our previous results24,32,33).
Cell line culture and drug treatments and cell viability assay.
Lung cancer cell lines H1299, H299, Calu1, H460, H1975, H1650, Calu3 and
HCC827 were obtained from ATCC (Manassas, VA, USA) and grown in 10% fetal
bovine serum containing complete RPMI medium (Gibco-Invitrogen). The cell lines
were obtained directly from the ATCC that performs cell line characterizations or
authentication by the short tandem repeat profiling and passaged in our laboratory
for ˂6 months after receipt. For drug treatments and cell viability assays, 3000 cells
were plated in triplicate in 96-well plate and left untreated or exposed for 3 days to
the following drugs before CellTiter-Glo evaluation (Promega, Madison, WI, USA):
10 μM erlotinib, 10 μM gefitinib and 100 μg/ml cetuximab.
Chemotherapy and erlotinib treatment. A total of 3000 cells obtained
from sphere dissociation were plated in 96-well flat-bottom plates. Chemother-
apeutic agents (Sigma, St. Louis, MO, USA) were added at the following final
concentrations: cisplatin 1 μg/ml, gemcitabine 50 μM, docetaxel 0.5 μg/ml,
pemetrexed 100 μg/ml and etoposide 5 μg/ml; EGFR inhibitor erlotinib (Genentech,
South San Francisco, CA, USA) at the final concentration of 10 μM. Cell viability
was evaluated by both luminescent cell viability assay (CellTiter-Glo, Promega) and
cell count by Trypan blue exclusion. For soft agar assay, 500 single cells were plated
in the top agar layer in each well of a 24-well culture plate with 0.3% top agar layer
and 0.4% bottom agar layer (SeaPlaque Agarose, Cambrex, NJ, USA). Cells were
cultivated at 37 °C for 3 weeks and colonies from triplicate wells were stained with
crystal violet (0.01% in 10% MetOH), visualized and counted under microscope.
Western blot. For immunoblotting studies, 20 μg of proteins from each sample
were resolved on 4–12% polyacrylamide gel electrophoresis NuPAGE Bis-Tris
(Invitrogen, Carlsbad, CA, USA) and transferred to nitrocellulose membranes.
Rabbit polyclonal anti-Phospho-EGFR (Tyr1068), -Phospho-EGFR (tyr1173),
-Phospho-Akt (Ser473) -Akt, -Caspase-3 (8G10) and -Phospho-Stat3 (Ser727)
and mouse monoclonal anti-STAT3 were purchased from Cell Signaling (Beverly,
MA, USA). Mouse monoclonal anti-PTEN was purchased from BD (Franklin Lake,
NJ, USA), mouse monoclonal anti-Phospho-ERK clone (E-4), rabbit polyclonal anti-
EGFR (1005), -Bcl xL (H5), -Erk and -Notch3 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA) and mouse monoclonal β-tubulin and α-actin
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Peroxidase-conjugated
secondary antibodies were purchased from Amersham Pharmacia Biotech
(Buckinghamshire, UK).
Apoptosis assay. For apoptosis assay 1 × 105 cells were washed with PBS
and resuspended in Nicoletti buffer (0.1% sodium citrate, pH 7.4/0.1% Triton X)
containing 100 μg/ml propidium iodide and 200 μg/ml RnaseA. After 2 h of
incubation at 4 °C, samples were analyzed with FACSCAN (Beckton Dickinson).
Xenograft generation and mice treatments. Cell suspensions of ADC
and SCC CSC lines were mixed 1 : 1 with growth factor-reduced Matrigel (BD) and
injected subcutaneously in the flanks of 4-week-old female NSG (NOD/SCID
nonobese diabetic/severe combined immunodeficiency gamma chain deficient) mice
(Charles River, Wilmington, MA, USA). For drug treatment, when tumors reached a
mean of 0.5 cm diameter, mice were treated with vehicles, erlotinib (100 mg/kg/
5 days on and 2 days off/gavage) freshly dissolved in 0.5% hydrossimethylcellulose/
0.1% Tween-80, chemotherapeutic agent combinations as cisplatin (3 mg/kg
/biweekly/intraperitoneally (IP)) + pemetrexed (200 mg/kg /biweekly/IP) or cisplatin
(3 mg/kg /biweekly/IP) + gemcitabine (60 mg/kg /biweekly/IP). Tumors were
measured once a week for the 4 weeks using a caliper, and mice were monitored
for signs of drug-induced toxicity and weighed regularly. At the end of treatments,
tumors were monitored for 3–5 weeks or collected and dissociated to obtain cell
suspension as indicated above and previously reported.24
Immunohistochemistry on tumor sections. EGFR expression was
detected by IHC using EGFR PharmDX kit (Dako, Glostrup, Denmark) according to
the manufacturer’s instructions. Antigen retrieval was performed treating sections by
proteinase K. Phospho-EGF Receptor (Tyr1173) (EGFRtyr1173) and Phospho-EGF
Receptor (Tyr1068) (EGFRtyr1068) expression was detected by IHC using specific
monoclonal antibodies (Cell Signaling). Antigen retrieval was performed at 96 °C
using a 10 mM EDTA buffer, pH 8, for 40 min in a thermostatic bath.
Diaminobenzidine (DAB) was used as chromogenic substrate. EGFR, p-EGFRtyr1068
and p-EGFRtyr1173 were interpreted according to the follow scoring criteria: negative,
no reaction; 1+, 2+ or 3+, if neoplastic cells displayed a weak, moderate or strong
plasmamembrane immunostaining, respectively.
Statistical analysis. The statistical significance of the results was evaluated
by ANOVA and Bonferroni post tests. All statistical tests were performed using
GraphPad Prism v.4.0 for Windows (GraphPad Software, San Diego, CA, USA,
www.graphpad.com) and the threshold for statistical significance was set at 0.05.
P-values are displayed on the graphs using a single asterisk for significances
ranging from 0.05 to 0.01, two asterisks for values between 0.01 and 0.001 and
three asterisks for values below 0.001.
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